What kind of medicine is Vigabatrin and is it effective?

Vibatrin, also known as vigabatrin, is a drug that irreversibly inhibitsGABA transaminase. It is administered orally, absorbed quickly and safely, and has a bioavailability of 60-80%. It reaches peak blood concentration within about 2 hours after taking it and does not bind to plasma proteins. The drug has a half-life of 5-7 hours, and most (75-95%) is excreted unchanged through the kidneys. It is worth noting that Vigabatrin can reduce the concentration of RHT in the blood, but only by about 30%.

Vibatrin is widely used to treat epilepsy, especially partial and generalized seizures that are refractory to other antiepileptic drugs. Its therapeutic mechanism is to irreversibly inhibit GABA aminotransferase, thereby increasing the concentration of GABA (γ-aminobutyric acid) in the brain. GABA is an important inhibitory neurotransmitter in the central nervous system and plays a key role in controlling the excessive excitability of neurons. Therefore, Vigabatrin is effective in reducing the frequency and severity of epileptic seizures.

Infantile spasms is a severe epileptic encephalopathy in infants and young children, characterized by characteristic spasms and EEG peak rhythm disorders. Vigabatrin has also shown significant efficacy in the treatment of infantile spasms and can be used as an auxiliary treatment to help control spasms, thereby improving the quality of life and prognosis of children.

In addition to the two main diseases mentioned above, Vigabatrin may also have certain effects on other forms of epileptic seizures, such as Lennox-Gastaut syndrome. In addition, some studies suggest that vigabatrin may also have a role in improving tardive dyskinesia.

Although Vigabatrin has shown certain efficacy in treating diseases such as epilepsy, it may also cause some side effects. Common side effects include drowsiness, fatigue, weight gain, dizziness, headache, nervousness, poor memory, depression, agitation, double vision, and reduced visual field. In addition, there are some more serious side effects that require special attention.

Vigabatrin may cause a decrease in hemoglobin and hematocrit, and cases of significant decreases in hemoglobin or hematocrit have been reported. Vigabatrin may cause central nervous system depression, which may impair physical or mental abilities. Therefore, patients must be cautioned not to perform tasks that require mental alertness, such as operating machinery or driving.

Peripheral edema and edema with symptoms such as hypertension, heart failure, weight gain, and renal or hepatic insufficiency have been reported after taking Vigabatrin. Intramyelin edema has been reported in infants, and patients must be closely monitored for potential neurotoxicity. In addition, adult patients may develop peripheral neuropathy, manifested by symptoms such as numbness or tingling in the toes or feet, diminished vibration or position sensation in the distal lower extremities, or progressive loss of reflexes.

Pregnant and lactating women should avoid taking Vigabatrin to avoid affecting the health of the fetus or baby. Vigabatrin should not be taken when suffering from acute illnesses such as colds and fevers to avoid aggravating symptoms. While taking Vigabatrin, patients should follow the doctor's instructions for regular examinations and monitoring of relevant indicators to ensure the safety and effectiveness of the medication.